UltraDx Secures Nearly RMB 100 Million in Series A Funding and Partners with Quanterix to Accelerate Early Diagnosis of Alzheimer’s Disease in China

VCBeat has learned that UltraDx recently announced the successful completion of its first round of financing, amounting to nearly RMB 100 million. Investors included world-leading venture capital firms such as ARCH and GF Holdings. Meanwhile, the company also announced a partnership with Quanterix, a leader in proteomics, to jointly accelerate the clinical implementation of Simoa technology in China.

UdiBio is led by an industry-leading, experienced team and anchored by investment from top-tier global funds, leveraging the globally leading Simoa^®Established through the organic integration of the introduction and localization of the digital single-molecule immunoassay technology platform.

Prevention and treatment of Alzheimer’s disease (AD) is a global challenge. The current primary diagnostic approach combines PET-CT imaging with cerebrospinal fluid (CSF) sampling via lumbar puncture to detect protein biomarkers. This method is costly, diagnostically delayed, and causes significant patient discomfort, making it unsuitable for widespread adoption in early screening and diagnosis due to its high economic and time costs as well as poor patient experience.

Simoa technology enables truly digital, ultra-sensitive immunoassays at the single-molecule level. With its attogram-level detection sensitivity, it can accurately detect trace amounts of Alzheimer’s disease (AD) biomarkers in peripheral blood samples, significantly advancing the diagnostic window. Furthermore, its non-invasive sampling method substantially reduces patient discomfort and improves compliance.

Youdi Biotech leverages the Simoa platform to localize detection equipment and reagent products for clinical application. Adopting a hybrid model of “overseas introduction + domestic inception,” with Alzheimer’s disease as its entry point, the company focuses on five major therapeutic areas—neurological disorders, oncology, immunology, cardiovascular diseases, and infectious diseases—to build leading disease screening and auxiliary precision diagnostic products, services, and multi-dimensional application platforms in China and worldwide.

The company now boasts a comprehensive team with functions spanning R&D, technology transfer, manufacturing, clinical registration, quality management, and business development (BD) for clinical research and service collaborations. With strong execution capabilities, the team operates R&D and production centers in Shanghai, Shijiazhuang, and other locations. The company has obtained medical device filing numbers and is accelerating efforts toward the registration of instruments and reagents, as well as service upgrades.

Jay Dong, Founder and CEO of UltraDxstated: “I am delighted and enthusiastic to announce that, by integrating cutting-edge Simoa technology,”Leveraging the first-mover advantage in a blue-ocean market, the Company’s abundant resources, and the funds raised in this offering,The company has taken a significant step toward its mission of making the world healthier and has completed its first round of financing. We are committed to collaborating with leading scientists and clinicians to advance early diagnosis of Alzheimer’s disease (AD) and other neurodegenerative diseases, cancer, immune disorders, cardiovascular diseases, and infections, thereby enabling early intervention and treatment.

Dong Zengjun, Founder, Chairman/CEO of UltraDx, a scientist-entrepreneur,

Co-founder of the Precision Medicine and Companion Diagnostics Committee, Chinese Society for Biotechnology

Vice President of the U.S.-Returned Scholars Branch of the Western Returned Scholars Association in Shanghai; Co-Chair of the Board of Directors of the Peking Union Medical College Overseas Alumni Association

UltraDx’s Founder and CEO, Dong Zengjun, is a scientist-entrepreneur who studied at the Massachusetts Institute of Technology (MIT, MBA), Peking Union Medical College (now Peking Union Medical College–Tsinghua University School of Medicine), and The Fletcher School of Law and Diplomacy at Tufts University.

Prior to founding UltraDx, he conducted immunological research and antibody development at Tufts University School of Medicine and its affiliated hospitals, as well as at Millennium Pharmaceuticals. He subsequently held senior leadership positions including Product Marketing Manager at BD, a Fortune 500 company; President of SME (CST) Asia Pacific and Founding General Manager of its China subsidiary; and Global Vice President.

He has also served as a Visiting Professor at the Medical Research Institute of Wuhan University, a Director of the Sino-American Biopharmaceutical Professionals Association (SABPA), a Director and Vice Chairman of BayHelix, and Chairman of the MIT Shanghai Alumni Board.

Regarding this financing,Keith Crandell, Managing Partner at ARCHstated, “We are thrilled and confident about leveraging Simoa to advance early diagnostic research for Alzheimer’s disease and other conditions in China. We will fully commit financial and technical resources to translating this breakthrough technology into products and solutions for research and diagnostics, thereby helping patients and their families worldwide.”

Charles Lin, CEO of GF Holdings (Hong Kong) Corporation Limited“We are excited about this technology and its potential, and we are impressed by Mr. Dong’s passion, energy, and leadership. GF Holdings (Hong Kong) Corporation Limited will fully support this company, which offers solutions for the vast blue-ocean market of early Alzheimer’s disease diagnosis, with the hope that patients will benefit as soon as possible.”

UltraDx Founder and CEO Dong Zengjunstated: “At the same time, we are thrilled about Quanterix’s Simoa technology and its potential applications in clinical diagnostics. We announce that we will join forces with Quanterix to accelerate the clinical implementation of Simoa technology in China. We firmly believe that, leveraging our advantages in blue-ocean markets, supported by top-tier venture capital, built upon a world-leading technology platform, and driven by a team that is both passionate and capable, we will make significant contributions to the early diagnosis of diseases such as Alzheimer’s disease, promoting early detection and treatment, and ultimately bringing hope to patients and their families.”

Mr. Masoud Toloue, CEO of Quanterix CorporationHe further added, “We believe that early detection is a critical starting point for disease treatment. The ultra-high sensitivity of Simoa technology enables the early discovery of Alzheimer’s disease (AD) biomarkers that are otherwise undetectable or not detectable at an early stage in blood. We believe that our collaboration with Udi Biologics on IVD product development and commercialization in China will accelerate and improve the early diagnosis of Alzheimer’s disease.”

UltraDx is led by an industry-leading, experienced team and backed by top-tier global funds, leveraging the globally leading Simoa^®Established through the organic integration of the introduction and localization of digital single-molecule immunoassay technology platforms. By leveraging the Simoa platform to facilitate the local deployment of testing equipment and reagent products, as well as their clinical application, and relying on a hybrid model of “overseas introduction + domestic inception,” the company focuses on Alzheimer’s disease as an entry point. It centers on five major disease areas—neurological disorders, oncology, immunology, cardiovascular diseases, and infectious diseases—to build leading disease screening and auxiliary precision diagnostic products, services, and multi-dimensional application platforms in China and worldwide.

Youdi Bio has established comprehensive team functions encompassing R&D, technology transfer, manufacturing, clinical registration, quality management, business development, clinical research, and service collaboration. With strong execution capabilities, the company operates R&D and production centers in Shanghai, Shijiazhuang, and other locations. It has obtained medical device filing numbers and is accelerating efforts toward the registration of instruments and reagents, as well as service upgrades. Youdi Bio is committed to working with industry peers to drive sector development, fulfill its responsibility in advancing early diagnosis for patients, and contribute to a healthier and better world.